Diabesity: therapeutic options

Colagiuri, Stephen

doi:10.1111/j.1463-1326.2009.01182.x

Cited by 102 publications

(67 citation statements)

References 140 publications

(213 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In developing countries, people aged 40 to 60 years (that is, working age) are affected most, compared with those older than 60 years in developed countries (Shaw et al, 2010). This increase in type 2 diabetes is inextricably linked to changes towards a Western lifestyle (high diet with reduced physical activity) in developing countries and the rise in prevalence of overweight and obesity (Chan et al, 2009;Colagiuri, 2010). There are approximately 1.4 million people with diagnosed type 2 diabetes in the UK (Bennett et al, 1995).…”

Section: Epidemiology and Etiology Of Type 2 Diabetes (Niddm)mentioning

confidence: 99%

The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus

Ozougwu¹,

Obimba²,

Belonwu³

et al. 2013

J. Physiol. Pathophysiol.

483

310

View full text Add to dashboard Cite

The aim of this paper is to review the information on type 1 and type 2 diabetes with emphasis on its etiology, pathogenesis and pathophysiology via literature review. Diabetes is a group of metabolic disorders characterized by a chronic hyperglycemic condition resulting from defects in insulin secretion, insulin action or both. Type 1 diabetes is the result of an autoimmune reaction to proteins of the islets cells of the pancreas while type 2 diabetes is caused by a combination of genetic factors related to impaired insulin secretion, insulin resistance and environmental factors such as obesity, overeating, lack of exercise and stress, as well as aging. The pathogenesis of selective β-cell destruction within the islet in type 1 diabetes mellitus is difficult to follow due to marked heterogeneity of the pancreatic lesions. At the onset of overt hyperglycemia, a mixture of pseudoatrophic islets with cells producing glycogen, somatostatin and pancreatic polypeptide, normal islets and islets containing both β-cells and infiltrating lymphocytes and monocytes may be seen. The autoimmune destruction of pancreatic β cells leads to a deficiency of insulin secretion that leads to the metabolic derangements associated with type 1 diabetes. The main pathophysiological features of type 2 diabetes are impaired insulin secretion and increased insulin resistance. The impairment of pancreatic β cell function notably shows progression overtime in type 2 diabetes although aging, obesity, insufficient energy consumption, alcohol drinking, smoking, etc are independent risk factors of pathogenesis of type 2 diabetes mellitus.

show abstract

Section: Epidemiology and Etiology Of Type 2 Diabetes (Niddm)mentioning

confidence: 99%

The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus

Ozougwu¹,

Obimba²,

Belonwu³

et al. 2013

J. Physiol. Pathophysiol.

483

310

View full text Add to dashboard Cite

show abstract

Section: Rycina 3 Korelacja Pomiędzy Wisfatyną a Hba 1c W Grupie A mentioning

confidence: 99%

“…"Lipotoxicity" and the resulting oxidative stress may contribute to the decline in b-cell mass and diminished insulin secretion [12]. Obesityassociated changes in circulating adipocytokines may contribute to both B-cell destruction and increased insulin resistance [12,13]. Visfatin, an adipocytokine with insulin-mimetic activity [1] and proinflammatory actions [8], is considered as a potential factor that may contribute to the development of diabetes in obese individuals.…”

Section: Rycina 3 Korelacja Pomiędzy Wisfatyną a Hba 1c W Grupie A mentioning

confidence: 99%

Stężenie wisfatyny u osób z otyłością w zależności od obecności świeżo wykrytych zaburzeń gospodarki węglowodanowej

Kamińska

Kopczyńska

Bieliński

et al. 2015

Endokrynologia Polska

View full text Add to dashboard Cite

 Visfatin concentrations in obese patients in relation to the presence of newly diagnosed glucose metabolism disordersStężenie wisfatyny u osób z otyłością w zależności od obecności świeżo wykrytych zaburzeń gospodarki węglowodanowej AbstractIntroduction: Visfatin, protein secreted by visceral adipose tissue, exerts insulin-mimetic actions. Visfatin concentration increases in patients with longer-standing diabetes type 2 with progressive b-cell dysfunction. Data about the role of visfatin in newly diagnosed glucose metabolism abnormalities are limited. Evaluation of visfatin concentration in patients with obesity, in relation to the presence of newly diagnosed glucose metabolism disorders. Material and methods:The study included 68 subjects with obesity, without a previous diagnosis of abnormal glucose metabolism. In all subjects we performed an oral glucose tolerance test, and according to the results the group was divided into the subgroups: A (n = 31), with glucose metabolism disorders (impaired fasting glucose, impaired glucose tolerance and type 2 diabetes); and B (n = 37), without abnormalities. In all subjects serum lipids, uric acid, C-peptide, glycated haemoglobin (HbA 1c ), creatinine, and serum visfatin concentrations were measured. The control group comprised 30 lean, healthy individuals with normal glucose tolerance. Results: We found elevated visfatin levels in obese individuals versus the control group (50.0 ± 48 vs. 26.7 ± 22.1 ng/mL; p = 0.01). Visfatin concentrations in both subgroups, A and B, did not differ (40.86 ± 27.84 vs. 57.7 ± 59.79 ng/mL; p = 0.19). In subgroup A visfatin concentration correlated significantly with triglycerides (r = 0.37, p = 0.038), HbA 1c (r = -0.43, p = 0.02), C-peptide (r = -0.38,p = 0.048), and waist-hip ratio (r = -0.41, p = 0.036). Conclusions: The presence of newly diagnosed glucose metabolism abnormalities in obese subjects had no influence on the visfatin level, probably due to preserved endogenous insulin secretion and relatively short exposure to hyperglycaemia in patients with prediabetes or at early stage of type 2 diabetes. (Endokrynol Pol 2015; 66 (2): 108-113)

show abstract

“…Moreover, considering the high risk of cardiovascular disease, the control of blood lipid profile must be considered (Colagiuri, 2010).…”

Section: Discussionmentioning

confidence: 99%

Comparative performance of lab tests and blood testing device to monitor glucose, total cholesterol and triacylglycerol in type 2 diabetic patients

Zubioli

Batista

Stefanello

et al. 2011

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

The performance of lab tests (LT) and blood testing devices (BTD) to monitor glycemia vs. glycated hemoglobin A1c (A1c) were compared. In addition, the performance of blood glucose, total cholesterol (TC) and triacylglycerol measured by LT and BDT were compared. All parameters were measured based on the same blood samples from overnight fasted type 2 diabetic patients (T2DP). Linear regression analysis was used for all comparisons. The results showed that A1c correlated better with LT-glucose (r = 0.58) than BTD-glucose (r = 0.42). Moreover, LT vs. BTD showed r values of 0.90, 0.82 and 0.92 for glucose, TC and triacylglycerol, respectively. It was concluded that the performance of LT-glucose was better than BDT-glucose. Moreover, since triacylycerol and TC measured by BTD correlated better with LT compared to BDT-glucose vs. LT-glucose, the inclusion of BTD-TC and BTD-triacylglycerol for detecting and monitoring hyperlipidemia in T2DP should be considered.Uniterms: Laboratory tests. Glycated hemoglobin. Glycemia. Total cholesterol. Triacylglycerol. Type 2 diabetes.Comparou-se a performance de avaliação da glicemia através de dosagens laboratoriais (DL) ou dispositivo para teste de sangue capilar (DTSC) vs. hemoglobina glicada A1c (A1c). Comparou-se ainda a performance de avaliação da glicemia, colesterol total (CT) e triacilglicerol (DL vs. DTSC). Avaliou-se estes parametros a partir das mesmas amostras de sangue coletadas em pacientes diabéticos tipo 2 (PDT2) em jejum noturno, sendo as comparações realizadas através de análise de regressão linear. A A1c correlacionou-se melhor com a glicemia-DL (r = 0,58) em relação a glicemia-DTSC (r = 0,42). Comparou-se DL vs. DTSC obtendo se r = 0,90, 0,82 e 0,92 para glicemia, CT e triacilglicerol, respectivamente. Concluiu-se que houve melhor performance da glicose-DL em relação a glicose-DTSC. Além disso, considerando que o triacilglicerol e TC avaliado através de DTSC correlaciona-se melhor com DL em comparação a DTSC-glicose vs. DL-glicose, a inclusão de DTSC-TC e DTSC-triacilglicerol visando detectar e monitorar hyperlipidemia in PDT2 deve ser considerada.

show abstract

Diabesity: therapeutic options

Cited by 102 publications

References 140 publications

The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus

The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus

Stężenie wisfatyny u osób z otyłością w zależności od obecności świeżo wykrytych zaburzeń gospodarki węglowodanowej

Comparative performance of lab tests and blood testing device to monitor glucose, total cholesterol and triacylglycerol in type 2 diabetic patients

Contact Info

Product

Resources

About